Bulk Pharmaceutical API Sources for TONOCARD

Bulk Pharmaceutical API Sources for TONOCARD

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		T0202_SIGMA
NIH Clinical Collection		SAM001246759
NovoSeek		38945
NovoSeek		108173
Hangzhou APIChem Technology		AC-16017

TONOCARD Bulk API Sourcing Analysis

Last updated: February 19, 2026

This report analyzes bulk Active Pharmaceutical Ingredient (API) sourcing for TONOCARD, focusing on key manufacturers, regulatory compliance, and market dynamics relevant to U.S. Food and Drug Administration (FDA) approved products. The analysis identifies primary API suppliers and assesses their impact on supply chain reliability and cost.

Who are the Primary Manufacturers of TONOCARD API?

The primary bulk API manufacturers for TONOCARD (generic name: Felodipine) supplying the U.S. market include a concentrated group of companies, primarily based in India and China, which are significant hubs for API production. These manufacturers are subject to rigorous FDA oversight and must adhere to Current Good Manufacturing Practices (cGMP).

• Divi’s Laboratories Limited: A major Indian API manufacturer, Divi's has historically been a significant supplier of dihydropyridine-class calcium channel blockers, including Felodipine. The company operates multiple FDA-inspected facilities, ensuring compliance with U.S. regulatory standards.
• Sun Pharmaceutical Industries Ltd.: As one of the largest generic pharmaceutical companies globally, Sun Pharma also manufactures its own API or sources it from highly regulated facilities. Their involvement in the Felodipine supply chain is notable due to their extensive U.S. market presence.
• Laurus Labs: Another prominent Indian API producer, Laurus Labs is known for its capabilities in complex chemistry and large-scale manufacturing. Their API production for cardiovascular drugs, including Felodipine, is subject to FDA audits.
• Major Chinese Manufacturers: While specific company names often fluctuate and are sometimes not publicly disclosed due to competitive reasons, several large-scale Chinese API producers are involved in the global Felodipine supply. These entities must meet FDA registration and inspection requirements for their products to be used in FDA-approved pharmaceuticals.

These manufacturers are critical to the TONOCARD supply chain. Their manufacturing capacity, quality control processes, and regulatory standing directly influence the availability and cost of the final drug product in the United States.

What are the Regulatory Requirements for TONOCARD API Suppliers?

API suppliers for TONOCARD must meet stringent regulatory standards set by the FDA to ensure product quality, safety, and efficacy.

• FDA Registration and Inspection: All API manufacturing facilities intended for use in the U.S. market must be registered with the FDA. Facilities are subject to periodic inspections to verify compliance with cGMP regulations (21 CFR Parts 210 and 211).
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to the FDA. A DMF contains proprietary information about the manufacturing, processing, packaging, and storage of an API. Pharmaceutical companies that use the API can then reference the DMF in their drug applications (e.g., Abbreviated New Drug Applications – ANDAs), allowing the FDA to review the API details without disclosing proprietary information to the drug product manufacturer.
• cGMP Compliance: Adherence to cGMP is paramount. This includes robust quality management systems, process validation, analytical method validation, control of raw materials, change control, and deviation management.
• Impurity Profiling and Control: Manufacturers must identify, characterize, and control impurities in the API, including genotoxic impurities. The FDA expects comprehensive impurity profiles and justification for acceptable impurity levels based on safety data.
• Supply Chain Security and Traceability: Regulations are increasingly focused on supply chain integrity. Manufacturers must have systems in place to prevent counterfeiting and ensure traceability of raw materials and finished API batches.

Failure to meet these requirements can result in import alerts, warning letters, and rejection of drug applications or marketing for finished products relying on the non-compliant API.

How Does API Sourcing Impact TONOCARD’s Market Competitiveness?

The sourcing strategy for TONOCARD's API significantly affects its market position, influencing cost of goods sold, supply chain resilience, and time-to-market for generic versions.

• Cost of Goods Sold (COGS): API manufacturing is a substantial component of overall drug production costs. Sourcing from manufacturers with lower production costs, due to economies of scale, efficient processes, or favorable labor and raw material prices (often found in India and China), can enable more competitive pricing for generic TONOCARD.
• Supply Chain Reliability: A diverse supplier base with robust manufacturing capabilities reduces the risk of drug shortages. Relying on a single API source, or a limited number of suppliers with potential for disruption (e.g., due to regulatory issues, geopolitical instability, or natural disasters), creates vulnerability. For a widely prescribed drug like TONOCARD, consistent availability is critical.
• Quality and Regulatory Assurance: While cost is a factor, the ability of API suppliers to consistently meet FDA quality and regulatory standards is non-negotiable. Pharmaceutical companies must conduct thorough due diligence on potential API partners, including site audits and review of regulatory compliance history. A history of FDA citations or import alerts for an API supplier can lead to significant delays or the need to re-source, impacting market entry or continued supply.
• Time-to-Market: For generic drug manufacturers seeking to launch a product, securing a reliable and compliant API source is an early and critical step. Delays in API qualification or sourcing can postpone the filing of ANDAs and subsequent market launch, allowing competitors to gain market share.
• Intellectual Property (IP) Considerations: While Felodipine is a well-established molecule with expired primary patents, process patents and polymorph patents can still influence manufacturing routes and preferred API suppliers. Sourcing from manufacturers who utilize non-infringing processes is essential.

The competitive landscape for generic TONOCARD is characterized by intense price pressure. Therefore, securing API from manufacturers who can balance cost-effectiveness with unwavering quality and regulatory compliance is a strategic imperative.

What are the Key Market Dynamics Affecting TONOCARD API Supply?

Several macroeconomic and industry-specific factors influence the global market for TONOCARD API.

• Global API Manufacturing Concentration: The API manufacturing sector for many established drugs, including Felodipine, is largely concentrated in India and China. This concentration offers cost advantages but also creates potential single-point risks within the global supply chain.
• Raw Material Availability and Cost: The synthesis of Felodipine requires specific chemical precursors. Fluctuations in the price and availability of these raw materials, influenced by global chemical markets and geopolitical events, can impact API production costs.
• Geopolitical Risks and Trade Policies: International trade policies, tariffs, and geopolitical tensions can affect the cost and logistics of importing APIs into the United States. For example, trade disputes can lead to increased duties or import restrictions, prompting pharmaceutical companies to diversify sourcing strategies.
• Environmental Regulations: Increasingly stringent environmental regulations in manufacturing hubs like China can lead to higher compliance costs for API producers, which may be passed on to buyers. This can also lead to temporary production halts if facilities need to upgrade to meet new standards.
• Increased FDA Scrutiny: The FDA continues to enhance its oversight of the global pharmaceutical supply chain, including API manufacturing. This includes more frequent and rigorous inspections, a focus on data integrity, and increased enforcement actions, which can disrupt supply from non-compliant facilities.
• Demand for Generic Cardiovascular Drugs: As the global population ages and cardiovascular diseases remain prevalent, the demand for effective and affordable treatments like generic Felodipine is sustained. This consistent demand supports a stable, albeit competitive, market for its API.

These dynamics necessitate ongoing monitoring by pharmaceutical companies to ensure a secure and cost-effective supply of TONOCARD API.

What is the Typical Lead Time for Securing TONOCARD API?

The lead time for securing bulk TONOCARD API can vary significantly, influenced by supplier inventory, production schedules, quality control testing, and shipping logistics.

• Standard Orders: For established relationships with reliable suppliers, typical lead times for API production and delivery can range from 8 to 16 weeks. This timeframe accounts for batch manufacturing, in-process testing, final quality release, and international shipping.
• New Supplier Qualification: If a pharmaceutical company needs to qualify a new API supplier, the process is considerably longer. This typically involves initial supplier assessments, site audits by the pharmaceutical company, submission and review of API quality data, and potentially the need for the supplier to undergo FDA inspection if they are not already approved for the U.S. market. This qualification process can add 6 to 12 months or more to the lead time before an order can even be placed for commercial quantities.
• Urgent Requirements: In cases of unexpected shortages or urgent market demands, lead times can be compressed, but this usually comes at a premium price and depends on the supplier's existing production capacity and willingness to expedite. Expedited production and shipping might reduce the overall lead time to 4 to 8 weeks, but this is not a standard option.
• Regulatory Hold-Ups: Any delays at the FDA’s end, such as during the review of a DMF amendment or if an import alert is issued for a supplier, can indefinitely extend lead times.

Effective inventory management and strong supplier relationships are crucial to mitigate risks associated with lead times and ensure consistent product availability for TONOCARD.

What are the Major Quality Control Parameters for TONOCARD API?

Ensuring the quality of TONOCARD API requires strict adherence to a defined set of control parameters, typically outlined in pharmacopoeial monographs and the API’s DMF.

• Assay: This measures the purity of the API, ensuring it contains the specified percentage of Felodipine. For example, it must typically be within 98.0% to 102.0% on a dried basis, as per USP monograph standards.
• Identification: Tests (e.g., infrared spectroscopy, high-performance liquid chromatography (HPLC) retention time) confirm that the substance is indeed Felodipine.
• Related Substances/Impurities: HPLC methods are used to detect and quantify process-related impurities and degradation products. Strict limits are set for individual known impurities, unknown impurities, and total impurities. For instance, specific known impurities might have limits of not more than 0.10%, while the limit for any individual unknown impurity might be not more than 0.20%, with total impurities not exceeding 1.0%.
• Residual Solvents: Gas chromatography (GC) is used to measure residual solvents from the manufacturing process. Limits are set based on ICH Q3C guidelines, categorizing solvents by their toxicity (e.g., Class 1, 2, and 3 solvents with specific ppm limits).
• Water Content: Karl Fischer titration determines the amount of water present, which can affect API stability and potency. Limits are typically very low, often not more than 0.5%.
• Heavy Metals: Tests ensure that levels of heavy metals (e.g., lead, mercury) are below specified limits, typically not more than 10 ppm or 20 ppm, depending on the monograph.
• Sulphated Ash/Residue on Ignition: This test measures the amount of inorganic residue remaining after incineration, indicating the level of inorganic impurities. The limit is generally not more than 0.1%.
• Particle Size Distribution: For solid oral dosage forms, the particle size of the API can significantly impact dissolution rates and bioavailability. Manufacturers often control and specify particle size ranges, particularly for extended-release formulations.

These parameters are critical for ensuring that the API is safe, effective, and performs as intended when formulated into the final TONOCARD dosage form.

Key Takeaways

• Bulk API manufacturing for TONOCARD is concentrated among a few large players, primarily in India and China, necessitating rigorous FDA oversight.
• Regulatory compliance, including cGMP adherence and successful DMF filings, is a non-negotiable requirement for API suppliers to the U.S. market.
• API sourcing directly influences the cost competitiveness, supply chain resilience, and market entry speed of generic TONOCARD products.
• Market dynamics such as global manufacturing concentration, raw material costs, geopolitical factors, and evolving environmental/FDA regulations shape API supply and pricing.
• Lead times for TONOCARD API can range from 8-16 weeks for standard orders, but new supplier qualification can add significantly more time.
• Stringent quality control parameters, including assay, impurity profiling, and residual solvents, are critical for ensuring TONOCARD API safety and efficacy.

FAQs

1. What are the primary risks associated with sourcing TONOCARD API from a single manufacturer?

Sourcing from a single manufacturer creates a critical dependency. Risks include supply disruptions due to the manufacturer's production issues (e.g., equipment failure, quality deviations, labor disputes), regulatory actions (e.g., FDA import alerts, warning letters), or geopolitical events impacting their region. This can lead to drug shortages, lost sales, and damage to market reputation.

2. How does the FDA ensure the quality of APIs imported from overseas manufacturers?

The FDA employs a multi-faceted approach. This includes requiring foreign facilities to register with the FDA, conducting pre-approval and routine inspections of these facilities to verify cGMP compliance, reviewing Drug Master Files (DMFs) submitted by API manufacturers, and analyzing imported products at ports of entry. The FDA also participates in international regulatory harmonization efforts.

3. What is the typical price range for bulk TONOCARD API on the global market?

Pricing for bulk TONOCARD API is subject to market forces, including supply and demand, raw material costs, and manufacturer scale. While specific real-time pricing is proprietary, it generally fluctuates, with costs often in the range of $50 to $200 per kilogram for well-established generics. This can vary based on volume, purity specifications, and contract terms.

4. How can pharmaceutical companies mitigate the risk of impurity-related issues with TONOCARD API?

Mitigation strategies include conducting thorough due diligence on potential API suppliers, including reviewing their quality management systems and historical FDA inspection reports. Pharmaceutical companies should also engage in rigorous incoming API testing, establish clear specifications for impurities based on ICH guidelines and pharmacopoeial standards, and maintain open communication with API manufacturers regarding any process changes that could affect impurity profiles.

5. Are there any significant emerging suppliers or technological advancements in TONOCARD API manufacturing that could disrupt the current market?

While Felodipine is an older molecule, advancements in green chemistry and continuous manufacturing processes are being explored across the API industry. These could lead to more efficient, cost-effective, and environmentally friendly production methods. Emerging suppliers are less common for established generics; the market is typically dominated by existing, large-scale manufacturers who have already invested in the necessary infrastructure and regulatory approvals. However, shifts can occur if a new entrant demonstrates significant cost or quality advantages and successfully navigates regulatory hurdles.

Citations

[1] United States Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA Website]

[2] United States Pharmacopeia. (n.d.). Felodipine Monograph. USP-NF Online.

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1995). Impurities: Guideline for Residual Solvents Q3C(R6).

[4] Divi's Laboratories Limited. (n.d.). Product Portfolio. Retrieved from [Divi's Website]

[5] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Sun Pharma Website]

[6] Laurus Labs. (n.d.). Product Offerings. Retrieved from [Laurus Labs Website]